What is the initial treatment for autoimmune hepatitis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 24, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Initial Treatment for Autoimmune Hepatitis

Start combination therapy with prednisone 30 mg/day (tapering to 10 mg/day over 4 weeks) plus azathioprine 1-2 mg/kg/day as the initial treatment for autoimmune hepatitis. 1, 2

Why Combination Therapy is Superior

Combination therapy produces significantly fewer corticosteroid-related side effects compared to prednisone monotherapy (10% versus 44%) while maintaining equivalent efficacy. 1, 3 This makes it the preferred regimen, especially in elderly patients who are at higher risk for steroid complications. 4

Specific Dosing Schedule

The standard induction regimen follows this taper: 1, 3

  • Week 1: Prednisone 30 mg/day + Azathioprine 50 mg/day (US) or 1-2 mg/kg/day (Europe)
  • Week 2: Prednisone 20 mg/day + Azathioprine (same dose)
  • Weeks 3-4: Prednisone 15 mg/day + Azathioprine (same dose)
  • Maintenance: Prednisone 10 mg/day + Azathioprine (same dose)

An alternative European approach starts prednisone alone for two weeks before adding azathioprine, particularly when bilirubin is below 6 mg/dL. 2

Treatment Duration and Monitoring

Continue treatment for at least 2 years and for at least 12 months after normalization of liver enzymes. 1, 2 The average duration of initial treatment is 18-24 months. 1, 3

Monitor response at 4-8 weeks after initiation—serum aminotransferases typically improve within 2 weeks of starting therapy. 3 Check aminotransferase levels monthly, as small decrements in prednisone dose can cause marked increases in enzyme levels. 3 Aim for complete normalization of both transaminases AND IgG levels, as persistent elevations predict relapse, ongoing histological activity, and progression to cirrhosis. 2

Special Populations Requiring Modified Approach

Patients with Cytopenia

Measure thiopurine methyltransferase (TPMT) activity before starting azathioprine to exclude homozygote TPMT deficiency. 1, 2 Use prednisone monotherapy in patients with severe pre-treatment cytopenia. 1 Only 0.3%-0.5% of the population has severe enzyme deficiency, making routine screening unnecessary unless cytopenia is present. 5

Non-Cirrhotic Patients at High Risk for Steroid Side Effects

Consider budesonide 9 mg/day plus azathioprine specifically in treatment-naive, non-cirrhotic patients with early-stage disease who have high risk for steroid complications (psychosis, poorly controlled diabetes, severe osteoporosis). 2 Do not use budesonide in cirrhotic patients due to loss of first-pass hepatic metabolism and safety concerns from portosystemic shunting. 6

Acute Severe Autoimmune Hepatitis

Treat immediately with high-dose intravenous corticosteroids (≥1 mg/kg) as early as possible. 2

Management of Treatment Failure

For non-responders after 2-3 years, increase to prednisone 60 mg daily alone or prednisone 30 mg daily with azathioprine 150 mg daily for at least 1 month. 5, 3 Alternative options for steroid-refractory cases include tacrolimus or cyclosporine. 1, 3

Prevention of Treatment Complications

All patients must receive: 1, 3, 2

  • Calcium and vitamin D supplementation from treatment initiation
  • DEXA scanning for bone mineral density at 1-2 year intervals
  • Vaccination against hepatitis A and B early in susceptible patients

Severe complications (osteoporosis, vertebral compression, diabetes, cataracts, hypertension, psychosis) typically develop after 18 months of therapy at prednisone doses >10 mg daily. 3

Expected Outcomes and Relapse Management

80-90% of patients achieve biochemical improvement with transaminases normalizing within 6 months in most responders. 2 However, relapse occurs in 50-90% of patients within 12 months of stopping treatment. 1, 3, 2 After relapse, use long-term maintenance with azathioprine 2 mg/kg/day—87% of adult patients remain in remission during median follow-up of 67 months. 1, 3

Common Pitfall to Avoid

Do not aim for merely reducing aminotransferases to below two times the upper limit of normal—this outdated approach is insufficient. 6 Complete normalization of both transaminases and IgG levels should be the goal, as anything less predicts poor outcomes. 2

References

Guideline

Initial Treatment for Autoimmune Hepatitis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Initial Medication Treatment for Autoimmune Hepatitis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Treatment of Autoimmune Hepatitis Type 2

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Therapeutic strategies for autoimmune hepatitis.

Digestive diseases (Basel, Switzerland), 2011

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.